180 related articles for article (PubMed ID: 37926711)
21. MicroRNA-375 Functions as a Tumor-Suppressor Gene in Gastric Cancer by Targeting Recepteur d'Origine Nantais.
Lian S; Park JS; Xia Y; Nguyen TT; Joo YE; Kim KK; Kim HK; Jung YD
Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27689991
[TBL] [Abstract][Full Text] [Related]
22. RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells.
Xu XM; Wang D; Shen Q; Chen YQ; Wang MH
Oncogene; 2004 Nov; 23(52):8464-74. PubMed ID: 15378025
[TBL] [Abstract][Full Text] [Related]
23. Recepteur d'origine nantais tyrosine kinase is a direct target of hypoxia-inducible factor-1alpha-mediated invasion of breast carcinoma cells.
Thangasamy A; Rogge J; Ammanamanchi S
J Biol Chem; 2009 May; 284(21):14001-10. PubMed ID: 19307182
[TBL] [Abstract][Full Text] [Related]
24. Activation of the RON receptor tyrosine kinase inhibits inducible nitric oxide synthase (iNOS) expression by murine peritoneal exudate macrophages: phosphatidylinositol-3 kinase is required for RON-mediated inhibition of iNOS expression.
Chen YQ; Fisher JH; Wang MH
J Immunol; 1998 Nov; 161(9):4950-9. PubMed ID: 9794431
[TBL] [Abstract][Full Text] [Related]
25. The effect of splicing MST1R in gastric cancer was enhanced by lncRNA FENDRR.
Zhou D; Zhu X; Wu X; Zheng J; Tou L; Zhou Y
Exp Ther Med; 2021 Aug; 22(2):798. PubMed ID: 34093754
[TBL] [Abstract][Full Text] [Related]
26. Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer.
Hu CY; Xu XM; Hong B; Wu ZG; Qian Y; Weng TH; Liu YZ; Tang TM; Wang MH; Yao HP
Front Oncol; 2019; 9():1377. PubMed ID: 31867280
[TBL] [Abstract][Full Text] [Related]
27. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression.
Thomas RM; Toney K; Fenoglio-Preiser C; Revelo-Penafiel MP; Hingorani SR; Tuveson DA; Waltz SE; Lowy AM
Cancer Res; 2007 Jul; 67(13):6075-82. PubMed ID: 17616662
[TBL] [Abstract][Full Text] [Related]
28. The MST1R/RON Tyrosine Kinase in Cancer: Oncogenic Functions and Therapeutic Strategies.
Cazes A; Childers BG; Esparza E; Lowy AM
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454943
[TBL] [Abstract][Full Text] [Related]
29. A novel RON splice variant lacking exon 2 activates the PI3K/AKT pathway via PTEN phosphorylation in colorectal carcinoma cells.
Ling Y; Kuang Y; Chen LL; Lao WF; Zhu YR; Wang LQ; Wang D
Oncotarget; 2017 Jun; 8(24):39101-39116. PubMed ID: 28388571
[TBL] [Abstract][Full Text] [Related]
30. Structural basis for the binding specificity of human Recepteur d'Origine Nantais (RON) receptor tyrosine kinase to macrophage-stimulating protein.
Chao KL; Gorlatova NV; Eisenstein E; Herzberg O
J Biol Chem; 2014 Oct; 289(43):29948-60. PubMed ID: 25193665
[TBL] [Abstract][Full Text] [Related]
31. The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells.
Feres KJ; Ischenko I; Hayman MJ
Oncogene; 2009 Jan; 28(2):279-88. PubMed ID: 18836480
[TBL] [Abstract][Full Text] [Related]
32. Small interfering RNA targeting of Recepteur d'Origine Nantais induces apoptosis via modulation of nuclear factor-kappaB and Bcl-2 family in gastric cancer cells.
Park JS; Park JH; Lee S; Joo YE; Jung YD
Oncol Rep; 2010 Sep; 24(3):709-14. PubMed ID: 20664977
[TBL] [Abstract][Full Text] [Related]
33. Chrysin inhibits cell invasion by inhibition of Recepteur d'origine Nantais via suppressing early growth response-1 and NF-κB transcription factor activities in gastric cancer cells.
Xia Y; Lian S; Khoi PN; Yoon HJ; Han JY; Chay KO; Kim KK; Jung YD
Int J Oncol; 2015 Apr; 46(4):1835-43. PubMed ID: 25625479
[TBL] [Abstract][Full Text] [Related]
34. Recepteur d'origine nantais contributes to the development of endometriosis via promoting epithelial-mesenchymal transition of a endometrial epithelial cells.
Yu Q; Wang J; Li T; Guo X; Ding S; Che X; Zhu L; Peng Y; Xu X; Zou G; Zhang X
J Cell Mol Med; 2021 Feb; 25(3):1601-1612. PubMed ID: 33410267
[TBL] [Abstract][Full Text] [Related]
35. Regulation of Macrophage Polarization by RON Receptor Tyrosine Kinase Signaling.
Chaudhuri A
Front Immunol; 2014; 5():546. PubMed ID: 25400637
[TBL] [Abstract][Full Text] [Related]
36. Collaborative activities of macrophage-stimulating protein and transforming growth factor-beta1 in induction of epithelial to mesenchymal transition: roles of the RON receptor tyrosine kinase.
Wang D; Shen Q; Chen YQ; Wang MH
Oncogene; 2004 Mar; 23(9):1668-80. PubMed ID: 15001985
[TBL] [Abstract][Full Text] [Related]
37. Blocking tumorigenic activities of colorectal cancer cells by a splicing RON receptor variant defective in the tyrosine kinase domain.
Wang MH; Lao WF; Wang D; Luo YL; Yao HP
Cancer Biol Ther; 2007 Jul; 6(7):1121-9. PubMed ID: 17611409
[TBL] [Abstract][Full Text] [Related]
38. Neuroprotective Role of the Ron Receptor Tyrosine Kinase Underlying Central Nervous System Inflammation in Health and Disease.
Dey A; Allen JN; Fraser JW; Snyder LM; Tian Y; Zhang L; Paulson RF; Patterson A; Cantorna MT; Hankey-Giblin PA
Front Immunol; 2018; 9():513. PubMed ID: 29616029
[TBL] [Abstract][Full Text] [Related]
39. RON, a tyrosine kinase receptor involved in tumor progression and metastasis.
Camp ER; Liu W; Fan F; Yang A; Somcio R; Ellis LM
Ann Surg Oncol; 2005 Apr; 12(4):273-81. PubMed ID: 15827676
[TBL] [Abstract][Full Text] [Related]
40. RON kinase isoforms demonstrate variable cell motility in normal cells.
Greenbaum A; Rajput A; Wan G
Heliyon; 2016 Sep; 2(9):e00153. PubMed ID: 27656686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
